FRANKLIN STREET ADVISORS INC /NC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
FRANKLIN STREET ADVISORS INC /NC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$425
+20.7%
60,000
+20.0%
0.04%
+26.7%
Q2 2023$352
-15.6%
50,0000.0%0.03%
-21.1%
Q1 2023$417
-27.4%
50,0000.0%0.04%
-30.9%
Q4 2022$574
-99.9%
50,0000.0%0.06%
-14.1%
Q3 2022$630,000
+19.1%
50,0000.0%0.06%
+28.0%
Q2 2022$529,000
-34.9%
50,0000.0%0.05%
-24.2%
Q1 2022$813,000
+17.3%
50,0000.0%0.07%
+26.9%
Q4 2021$693,000
-3.6%
50,0000.0%0.05%
-14.8%
Q3 2021$719,000
-9.1%
50,0000.0%0.06%
-9.0%
Q2 2021$791,000
+32.7%
50,000
-37.5%
0.07%
+15.5%
Q4 2020$596,000
+131.0%
80,000
+6.7%
0.06%
+107.1%
Q3 2020$258,000
-27.7%
75,0000.0%0.03%
-33.3%
Q2 2020$357,000
+138.0%
75,0000.0%0.04%
+90.9%
Q1 2020$150,000
-13.3%
75,000
+50.0%
0.02%
+10.0%
Q4 2019$173,000
-5.5%
50,000
-21.9%
0.02%
-13.0%
Q3 2019$183,000
+245.3%
64,000
+357.1%
0.02%
+228.6%
Q2 2019$53,000
-89.8%
14,000
-78.1%
0.01%
-90.4%
Q1 2019$521,000
+46.8%
64,000
+45.5%
0.07%
+30.4%
Q4 2018$355,000
+8.2%
44,000
+2.3%
0.06%
+27.3%
Q3 2018$328,000
+33.3%
43,0000.0%0.04%
+22.2%
Q2 2018$246,000
+5.1%
43,000
-12.2%
0.04%
+2.9%
Q1 2018$234,000
-2.9%
49,0000.0%0.04%
-2.8%
Q4 2017$241,000
-6.2%
49,0000.0%0.04%
-14.3%
Q3 2017$257,000
-5.5%
49,0000.0%0.04%
-10.6%
Q2 2017$272,000
-34.0%
49,0000.0%0.05%
-35.6%
Q1 2017$412,000
+32.9%
49,0000.0%0.07%
+32.7%
Q4 2016$310,000
+43.5%
49,0000.0%0.06%
+41.0%
Q3 2016$216,000
+10.2%
49,000
-29.0%
0.04%
+5.4%
Q2 2016$196,000
+0.5%
69,0000.0%0.04%
-5.1%
Q1 2016$195,000
-72.6%
69,0000.0%0.04%
-72.1%
Q4 2015$712,000
-9.5%
69,0000.0%0.14%
-10.3%
Q3 2015$787,000
-23.6%
69,0000.0%0.16%
-15.2%
Q2 2015$1,030,000
+65.3%
69,0000.0%0.18%
+61.4%
Q1 2015$623,000
-48.3%
69,000
-30.3%
0.11%
-50.2%
Q4 2014$1,204,000
+32.3%
99,000
+6.5%
0.23%
+32.4%
Q3 2014$910,000
-23.3%
93,0000.0%0.17%
-23.8%
Q2 2014$1,186,000
+20.5%
93,0000.0%0.23%
+15.2%
Q1 2014$984,000
-6.8%
93,000
-33.1%
0.20%
-7.5%
Q4 2013$1,056,000
+4.3%
139,0000.0%0.21%
-6.2%
Q3 2013$1,012,000
+368.5%
139,0000.0%0.23%
+328.3%
Q2 2013$216,000139,0000.05%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Sarissa Capital Management LP 7,637,700$77,675,0007.44%
Burrage Capital Management LLC 864,916$8,796,0007.13%
ORACLE INVESTMENT MANAGEMENT INC 2,367,670$24,079,0003.61%
HealthCor Management, L.P. 4,886,440$49,695,0001.76%
Ghost Tree Capital, LLC 500,000$5,085,0001.20%
Integral Health Asset Management, LLC 400,000$4,068,0001.16%
Lisanti Capital Growth, LLC 472,520$4,806,0000.62%
Parkman Healthcare Partners LLC 244,680$2,488,0000.58%
Baker Brothers Advisors 12,710,818$129,269,0000.56%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,605,380$26,497,0000.56%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders